Approaches to Japanese Dose Evaluation in Global Drug Development: Factors That Generate Different Dosages Between Japan and the United States

2011 ◽  
Vol 90 (6) ◽  
pp. 836-843 ◽  
Author(s):  
K Nakashima ◽  
M Narukawa ◽  
M Takeuchi
Keyword(s):  
United States ◽  
Drug Development ◽  
The United States ◽  
Dose Evaluation ◽  
Global Drug Development

A update of botanical drug development in the United States: Status of applications

Planta Medica ◽  
2015 ◽  
Vol 81 (11) ◽  
Author(s):  
KM Wu ◽  
C Wu ◽  
J Dou ◽  
H Ghantous ◽  
S Lee ◽  
...  
Keyword(s):  
United States ◽  
Drug Development ◽  
The United States ◽  
Botanical Drug

scholarly journals Implementation of a Market Entry Reward within the United States

2018 ◽  
Vol 46 (S1) ◽  
pp. 50-58 ◽  
Author(s):  
Gregory W. Daniel ◽  
Monika Schneider ◽  
Marianne Hamilton Lopez ◽  
Mark B. McClellan
Keyword(s):  
United States ◽  
Health Policy ◽  
Drug Development ◽  
Market Entry ◽  
The United States ◽  
Antimicrobial Drug ◽  
Multifactorial Approach

As part of a multifactorial approach to address weak incentives for innovative antimicrobial drug development, market entry rewards (MERs) are an emerging solution. Recently, the Duke-Margolis Center for Health Policy released the Priority Antimicrobial Value and Entry (PAVE) Award proposal, which combines a MER with payment reforms, transitioning from volume-based to “value-based” payments for antimicrobials. Here, the PAVE Award and similar MERs are reviewed, focusing on further refinement and avenues for implementation.

An Empirical Analysis of Japan's Drug Development Lag Behind the United States

2021 ◽  
Author(s):  
Hiroshi Nakamura ◽  
Naohiko Wakutsu ◽  
Satoshi Murayama ◽  
Takeshi Suzuki
Keyword(s):  
United States ◽  
Drug Development ◽  
Empirical Analysis ◽  
The United States
Sign in / Sign up

Export Citation Format

Share Document